This activity is supported by an educational grant from Ultragenyx.
page 1 of 5
Please click on Next tab to advance through activity.
Tell us what you think about Healio.com »
Get the latest news and education delivered to your inbox
©2018 Healio All Rights Reserved.
Activity Release Date: 10/25/2018; Activity Expiration Date: 10/25/2019
Time to Complete: 90 minutes
1.50 / AMA PRA Category 1 Credit™
X-linked hypophosphatemia (XLH) is a rare hereditary form of non-nutritional rickets that does not respond to vitamin D ingestion or ultraviolet radiation treatment. Many clinicians may have never seen a patient with XLH, delaying recognition and diagnosis. Greater understanding of the underlying pathophysiology of XLH, including involvement of PHEX and FGF-23, has led to the development and FDA approval of the first agent specifically developed for XLH - burosumab. Early treatment may lead to positive clinical outcomes, including improved bone mineralization and improved rickets in children, and improved healing of fractures in adults. This activity will provide current information about the genetics, diagnosis, consequences, and treatment of XLH in children and adults.
This activity is intended for endocrinologists, orthopedic surgeons, pediatricians, primary care providers, nephrologists and other healthcare professionals who are involved in the diagnosis and management of patients with X-Linked Hypophosphatemia.
Upon completion of the educational activity, participants should be able to:
AKH Inc., Advancing Knowledge in Healthcare is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points and 0 patient safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn 1.5 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.
NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.
Criteria for Success
Statements of credit will be awarded based on completing the pre-test, participant watching full video, scoring at least 70% on the post test, and completing an activity evaluation. A statement of credit will be available upon completion of an online evaluation/claimed credit form. You must participate in the entire activity to receive credit. There is no fee to participate in this activity. If you have questions about this CE activity, please contact AKH Inc. at email@example.com.
This activity is supported by an educational grant from Ultragenyx.
About our Faculty
Thomas O. Carpenter, MD
Professor of Pediatrics (Endocrinology) & Orthopaedics and Rehabilitation
Director, Yale Center for X-Linked Hypophosphatemia
New Haven, CT
Dr. Thomas Carpenter has been investigating disorders of mineral metabolism in children for over 35 years, maintains a special interest in X-linked hypophosphatemia (XLH). He has identified a number of major aspects of the human disease, characterizing the complications of hyperparathyroidism and enthesopathy. He contributed to the design and served as the principal investigator of the first-in-man use of KRN23, later named burosumab. He has worked with Ultragenyx to develop this program in children with XLH and has served as a lead investigator in the recent trials leading to approval in Europe and in the US of this drug. Dr. Carpenter is director of the Yale Center for X-Linked Hypophosphatemia (YC-XLH), and has contributed to numerous articles, reviews and textbook chapters related to rickets, other metabolic bone diseases, and disorders of calcium and phosphate homeostasis in children.
Dr. Carpenter has disclosed the following relevant financial relationships:
CONSULTANT: Ultragenyx; CONTRACTED RESEARCH: Ultragenyx—Investigator on trials that were contracted to Yale University
Karl L. Insogna, MD
Ensign Professor of Medicine (Endocrinology)
Yale School of Medicine
Director, Yale Bone Center
Yale Center for X-Linked Hypophosphatemia
New Haven, CT
Dr. Insogna began his clinical investigative career as a fellow, studying hypophosphatemic disorders, specifically X-Linked Hypophosphatemia, as well as the hypophosphatemia of renal stone formers. He was the first individual to show evidence for renal phosphate conservation in patients with XLH, despite the defect in renal tubular phosphate reabsorption. He was also the first individual to clarify the relationship between serum phosphate and absorptive hypercalciuria in patients with calcium oxalate stone disease. His work in hypophosphatemic disorders has continued uninterrupted over the last 30 years. He has worked closely with Dr. Thomas Carpenter from the Department of Pediatrics at Yale to explore the natural history of XLH and has undertaken a variety of studies aimed at developing new therapies for this skeletal dysplasia. He was the lead investigator for a recently published, international, double-blind RTC evaluating the role of a neutralizing antibody to FGF23 in the treatment of this disease. That study led directly to the approval of burosumab for the treatment of adults with XLH. He has also had experience with Hereditary Hypophosphatemic Rickets with Hypercalciuria and has published on this disease as well.
Dr. Insogna has disclosed the following relevant financial relationship:
CONSULTANT: Ultragenyx; CONTRACTED RESEARCH: Ultragenyx
Anthony A. Portale, MD
Professor of Pediatrics
Benioff Children’s Hospital
University of California San Francisco
San Francisco, CA
Dr. Anthony A. Portale, a pediatric kidney specialist, is an expert in genetic kidney and renal tubular diseases. He has a career-long clinical and research interest in vitamin D, phosphorus, and FGF23 metabolism. Through his National Institutes of Health-funded research, Portale contributed more than 80 publications to the medical and scientific literature focused on genetic and acquired disorders of calcium, phosphorus and vitamin D metabolism, and bone diseases in children.
Dr. Portale has disclosed the following relevant financial relationships:
CONTRACTED RESEARCH: Ultragenyx; SPEAKERS BUREAU: Ultragenyx
Lynne Kolton Schneider, PhD, Medical Writer/Interviewer: has disclosed no relevant financial relationships.
Dorothy Caputo, MA, BSN, RN, Lead Nurse Planner/Reviewer: has disclosed no relevant financial relationships.
Patricia Brignoni, AKH Director of Operations/Reviewer: has disclosed no relevant financial relationships.
Steve Eckert, AKH President & CEO, Planner/Reviewer: has disclosed no relevant financial relationships.
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review. AKH planners and reviewers have no relevant financial relationships to disclose.
Continuing Medical Education and Continuing Education
When you register for a Continuing Medical Education (CME) or a Continuing Education (CE) activity through one of our Web sites, we collect certain personally identifiable information from you such as your name, email address and mailing address. If you are a pharmacist and wish to receive CE credit, you are also required to provide your NAPB # and month and day of birth. For more information about NABP and CPE Monitor click here. In addition to personally identifiable information, we collect aggregated non-personally identifiable information about the activities undertaken by our users. We use the information that we collect through CME/CE activities in several ways:
HARDWARE AND SOFTWARE REQUIREMENTS
• A computer with an internet connection
• Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
• Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required